Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Co-marketing agreement between Thermo Fisher Scientific and TransMIT allows for high spatial and high mass resolution MSI platform to study complex biological tissues
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Report lays out blueprint for achieving Organon’s purpose and business imperatives to help women and girls achieve their promise through better health
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
RH Capital, a leading women's health venture capital fund, announced three new investments to improve health outcomes for women in the US.
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Subscribe To Our Newsletter & Stay Updated
